Published in Clin Dev Immunol on October 11, 2010
Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell (2013) 2.05
Meiotic recombination in mammals: localization and regulation. Nat Rev Genet (2013) 2.00
Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis (2011) 1.16
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res (2013) 0.93
Expression patterns of cancer-testis antigens in human embryonic stem cells and their cell derivatives indicate lineage tracks. Stem Cells Int (2011) 0.89
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res (2015) 0.89
Cross-analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation. OMICS (2012) 0.88
Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother (2013) 0.87
Nicotinic acetylcholine receptors induce c-Kit ligand/Stem Cell Factor and promote stemness in an ARRB1/ β-arrestin-1 dependent manner in NSCLC. Oncotarget (2014) 0.82
Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol (2013) 0.81
Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) (2012) 0.80
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines (2012) 0.79
DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine (2014) 0.79
SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget (2016) 0.78
T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it? Photochem Photobiol Sci (2015) 0.77
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol (2014) 0.77
Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein. PLoS One (2013) 0.75
Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget (2016) 0.75
Multicellular tumor spheroids of human uveal melanoma induce genes associated with anoikis resistance, lipogenesis, and SSXs. Mol Vis (2017) 0.75
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol (2001) 7.30
The DNA sequence of the human X chromosome. Nature (2005) 6.97
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell (1991) 5.02
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Krüppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A (1994) 4.84
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Imprinting a determined state into the chromatin of Drosophila. Trends Genet (1990) 4.04
Polycombing the genome: PcG, trxG, and chromatin silencing. Cell (1998) 3.97
Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 3.59
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet (1994) 3.10
The mouse X chromosome is enriched for multicopy testis genes showing postmeiotic expression. Nat Genet (2008) 2.95
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
The Krüppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proc Natl Acad Sci U S A (1994) 2.46
A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst (1999) 2.36
The human polycomb group complex associates with pericentromeric heterochromatin to form a novel nuclear domain. J Cell Biol (1998) 2.29
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J (1995) 2.14
Altered cellular proliferation and mesoderm patterning in Polycomb-M33-deficient mice. Development (1997) 2.00
Murine Polycomb- and trithorax-group genes regulate homeotic pathways and beyond. Trends Genet (1997) 1.95
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res (1996) 1.93
Transcriptional silencing of homeotic genes in Drosophila. Bioessays (1995) 1.88
The testis in immune privilege. Immunol Rev (2006) 1.77
Repression of transcriptional activity by heterologous KRAB domains present in zinc finger proteins. FEBS Lett (1995) 1.62
Altered DNA methylation and genome instability: a new pathway to cancer? Proc Natl Acad Sci U S A (1997) 1.60
SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer (1997) 1.60
Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol (2003) 1.57
The SSX gene family: characterization of 9 complete genes. Int J Cancer (2002) 1.46
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res (2002) 1.46
Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer (2001) 1.44
SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J Biol Chem (2001) 1.40
Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer (2001) 1.39
Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer (1999) 1.35
Reactivation of inactive X-linked genes. Dev Genet (1994) 1.34
Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet (1995) 1.34
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res (2004) 1.31
Immunological, paracrine and endocrine aspects of testicular immune privilege. Mol Cell Endocrinol (2010) 1.31
Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet (1988) 1.30
Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol (2010) 1.27
Expression of cancer testis genes in human brain tumors. Clin Cancer Res (2000) 1.25
Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res (2005) 1.25
Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res (2005) 1.24
Expression of SSX genes in human tumors. Int J Cancer (1998) 1.24
A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene (1998) 1.24
Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res (2000) 1.22
SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene (1999) 1.22
Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J Immunol (2001) 1.21
Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev (2002) 1.20
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ (1993) 1.20
Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci U S A (1987) 1.20
Activation of the glycoprotein hormone alpha-subunit promoter by a LIM-homeodomain transcription factor. Mol Cell Biol (1994) 1.18
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol (2009) 1.17
Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol (2000) 1.16
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer (2006) 1.14
Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res (1999) 1.13
The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet (1997) 1.13
Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Invest (1992) 1.10
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
Cytogenetics of synovial sarcoma: presentation of ten new cases and review of the literature. Genes Chromosomes Cancer (1991) 1.05
A consistent chromosome translocation in synovial sarcoma. Cancer Genet Cytogenet (1987) 1.04
Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. Hum Mol Genet (1997) 0.99
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol (2005) 0.99
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer (2002) 0.97
Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res (2003) 0.97
Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol (2002) 0.97
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol (2008) 0.97
SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother (2005) 0.97
Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous leukaemia and located on 9q33-34.1. Oncogene (1996) 0.97
Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med (2009) 0.96
DNA methylation changes during mouse spermatogenesis. Chromosome Res (1994) 0.95
The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer (2002) 0.95
Another synovial sarcoma with t(X;18) Cancer Genet Cytogenet (1987) 0.93
Expression of serologically identified tumor antigens in acute leukemias. Leuk Res (2003) 0.92
SSX expression in gynecological cancers and antibody response in patients. Cancer Immun (2004) 0.92
The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. Oncogene (2007) 0.91
The t(X;18)(p11.2;q11.2) translocation found in human synovial sarcomas involves two distinct loci on the X chromosome. Oncogene (1994) 0.91
Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res (2003) 0.91
Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma. Hum Pathol (2002) 0.90
Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett (2007) 0.90
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest (2004) 0.90
Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett (2001) 0.89
Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun (2005) 0.89
SSX2IP: an emerging role in cancer. Biochem Biophys Res Commun (2007) 0.89
Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression. Genomics (2003) 0.88
A novel chromosomal translocation t(1;14)(q25;q32) in pre-B acute lymphoblastic leukemia involves the LIM homeodomain protein gene, Lhx4. Oncogene (2002) 0.88
Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. Eur J Immunol (2002) 0.88
Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res (2003) 0.88
HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol (1998) 0.86
Delineation of the protein domains responsible for SYT, SSX, and SYT-SSX nuclear localization. Exp Cell Res (2000) 0.86
Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol (2009) 0.85
A new strategy of gene trapping in ES cells using 3'RACE. Transgenic Res (1995) 0.85
CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol (2005) 0.85
Expression of SSX genes in human osteosarcomas. Int J Cancer (2002) 0.84
SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol (2007) 0.83
Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res (2006) 0.82
Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol (2005) 0.82
Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines. Tissue Antigens (1980) 0.81
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res (2011) 1.66
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother (2006) 1.20
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol (2007) 1.14
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 1.11
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest (2009) 1.01
Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. Int J Urol (2006) 1.01
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother (2011) 0.97
Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines (2009) 0.96
Endothelin receptor antagonists in cancer therapy. Cancer Invest (2007) 0.95
Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol (2012) 0.95
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate (2007) 0.95
Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun (2006) 0.95
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res (2009) 0.94
Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J Clin Immunol (2004) 0.93
DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2010) 0.91
Immunotherapy for prostate cancer - recent progress in clinical trials. Clin Adv Hematol Oncol (2007) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Newer therapies in advanced prostate cancer. Clin Prostate Cancer (2004) 0.90
Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. J Immunother (2005) 0.90
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Invest New Drugs (2006) 0.89
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother (2007) 0.88
GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2007) 0.88
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. Prostate (2011) 0.86
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines (2012) 0.83
A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods (2013) 0.83
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology (2003) 0.81
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res (2008) 0.81
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate (2011) 0.80
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer (2013) 0.80
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate (2011) 0.79
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines (2012) 0.79
Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol (2013) 0.79
A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clin Genitourin Cancer (2005) 0.78
Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol (2013) 0.76
Sipuleucel-T: immunotherapy for advanced prostate cancer. Open Access J Urol (2011) 0.75
Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol (2010) 0.75
Methods for constructing and evaluating antitumor DNA vaccines. Methods Mol Biol (2009) 0.75